Here are the 10-K annual reports from Processa Pharmaceuticals, Inc. (PCSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add updated Part III information on governance, executive pay, ownership and auditor fees. The company reports a non-affiliate equity market value of about $8.1 million as of June 30, 2025 and 2,738,998 common shares outstanding as of April 29, 2026.
The amendment details board and committee composition, independence determinations, meeting activity in 2025, and compensation for key executives and directors, including salaries, bonuses and equity awards. It also outlines employment and severance terms, equity plan capacity, major shareholders, related-party arrangements and audit fees for 2024 and 2025.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on Next Generation Cancer (NGC) therapies that modify how existing chemotherapy drugs are metabolized or distributed to improve safety and efficacy. Its lead candidate, NGC-Cap (PCS6422 plus capecitabine), has completed a Phase 1B trial in refractory gastrointestinal cancers and is now in a global Phase 2 trial in advanced or metastatic breast cancer, temporarily paused after dosing 20 patients pending an interim analysis expected in the first half of 2026.
The company is also advancing NGC-Iri (PCS11T), a next-generation irinotecan, and is seeking to monetize two non-oncology assets, PCS12852 for gastroparesis and PCS499 for kidney disease. Processa emphasizes a proprietary Regulatory Science Approach aligned with FDA’s Project Optimus to select optimal dosing regimens and improve approval odds. As of March 13, 2026, it reported 2,660,039 common shares outstanding and held $1.4 million in Chiliz (CHZ) tokens with an unrealized gain of about $77,000 as part of an emerging digital asset treasury strategy.